Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies
Open Access
- 23 June 2014
- journal article
- research article
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 20 (2) , 140-147
Abstract
Objective: Depressive symptoms are common in schizophrenia and can worsen outcomes and increase suicide risk. Lurasidone is an atypical antipsychotic agent indicated for the treatment of schizophrenia and for the treatment of major depressive episodes associated with bipolar I disorder. This post hoc analysis evaluated the effect of lurasidone on depressive symptoms in patients with schizophrenia.Methods: Patient-level data were pooled from 4 similarly designed, double-blind, placebo-controlled, 6-week registration studies of lurasidone (40–160 mg/d) in adult patients with an acute exacerbation of schizophrenia. Changes in depressive symptoms, measured by the Montgomery–Åsberg Depression Rating Scale (MADRS), were analyzed for the overall sample and for subgroups of patients stratified by baseline MADRS scores.Results: MADRS assessments at baseline and endpoint (day 42 or last observation carried forward [LOCF]) were available for 1330 patients. Patients receiving lurasidone experienced significantly greater decreases in MADRS score (–2.8, least-squares [LS] mean change, LOCF) compared with patients receiving placebo (–1.4,P< .001, effect size 0.24). Analysis of change in MADRS score (LOCF) by baseline symptom severity (MADRS score of ≥12, ≥14, ≥16, ≥18) showed significantly greater improvement for lurasidone-treated patients across all severity groups; effect sizes ranged from 0.25 to 0.34. Among patients with a baseline MADRS score of ≥12, depressive symptom remission (defined as MADRS score P< .05).Conclusions: In a pooled analysis of short-term, placebo-controlled studies, lurasidone significantly improved depressive symptoms in patients with schizophrenia.Keywords
This publication has 41 references indexed in Scilit:
- Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtypeNeuropharmacology, 2013
- Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled studyPsychopharmacology, 2012
- Review: Suicide and schizophrenia: a systematic review of rates and risk factorsJournal of Psychopharmacology, 2010
- Lurasidone in the Treatment of Acute SchizophreniaThe Journal of Clinical Psychiatry, 2009
- Psychiatric Comorbidities and SchizophreniaSchizophrenia Bulletin, 2008
- The burden of depressive symptoms in the long-term treatment of patients with schizophreniaSchizophrenia Research, 2007
- A Systematic Review of the Prevalence of SchizophreniaPLOS Medicine, 2005
- Association of Depressive Symptoms With Worse Functioning in SchizophreniaThe Journal of Clinical Psychiatry, 2001
- Suicide and schizophreniaJournal of Psychopharmacology, 2001
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979